Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GW Pharma’s Cannabis-Derived Drug Shows Promise in Brain Cancer Study

By Ryan Bushey | February 8, 2017

British-based GW Pharmaceuticals received more good news regarding its cannabis-based drug development efforts.

The drug-maker published positive Phase 2 data from an exploratory placebo-controlled study testing a combination treatment of active cannabis ingredients tetrahydrocannabinol and cannabidiol (THC: CBD) on 21 patients diagnosed with an aggressive brain tumor called recurrent glioblastoma multiforme (GBM).  

GW started the study with an initial safety phase so the investigators could gage the safety of THC: CBD in conjunction with dose-intense temozolomide, which is used as the standard first-line treatment for GMB.

Next, the team moved into the randomized placebo-controlled phase where 12 patients received THC: CBD as an add-on therapy whereas the remainder were administered the placebo with the standard of care.

Results from this study had shown patients with documented recurrent treatment getting treated with THC: CBD saw an 83 percent one year survival rate versus 53 percent for those receiving placebo.

“The findings from this well-designed controlled study suggest that the addition of a combination of THC and CBD to patients on dose-intensive temozolomide produced relevant improvements in survival compared with placebo and this is a good signal of potential efficacy,” said principal investigator and oncology professor Susan Short, Ph.D., in a statement.

The company’s announcement elaborated that the THC and CBD components appeared to act through distinct signaling pathways in a manner similar to what was seen in preclinical animal models of glioma.

“Moreover, the cannabinoid medicine was generally well tolerated. These promising results are of particular interest as the pharmacology of the THC: CBD product appears to be distinct from existing oncology medications and may offer a unique and possibly synergistic option for future glioma treatment,” continued Short.

GW will use this data to consult with experts and regulatory agencies on building out a clinical development program for THC: CBD while expanding their oncology R&D efforts with cannabinoid candidates.

Other drugs in GW’s pipeline include lead candidate Epidiolex, which is being tested as a therapy for two-treatment resistant forms of epilepsy, and Sativex that is being trialed for anxiety disorders.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE